Tesaro's stock is surging higher ahead of the potential approval of a game-changing drug for ovarian cancer.
Johnson & Johnson has a good dividend. But AbbVie, Bristol-Myers Squibb, and Pfizer lay claim to much better yields.
AbbVie beats out Bristol-Myers Squibb, Johnson & Johnson, Novo Nordisk, Roche, and Teva to claim the prize of best big pharma dividend stock.
Is a spin-off of one of its business segments in the cards for Johnson & Johnson this year? Stranger things have happened before.
Will AbbVie face a rocky road in the new year because of these significant risks?
It was a banner year for companies developing drugs associated with compounds found in marijuana.
AstraZeneca's shares continued their downward spiral last month, falling by more than 8%.
Here's how Axim Biotechnologies, CoLucid Pharmaceuticals, Corbus Pharmaceuticals, Exelixis, and Tesaro outperformed their peers this year, and their outlooks for 2017
If you're looking for stocks that combine solid dividends and growth potential, drugmakers Bristol-Myers Squibb, AbbVie, and Lilly might be right for you.
AbbVie shares sank Friday on disappointing Q3 results. Here's what management had to say.